Bempedoic Acid in PPCI Impact on Clinical Outcome and Inflammatory Markers
Trial statusNot yet recruiting
Trial phaseNot listed
Trial typeObservational
Biological sexAll
Age18+
SponsorAssiut University
About this trial
Bempedoic acid in PPCI
Eligibility criteria
This trial accepts healthy volunteersQualifiers
None
Disqualifiers
None
Trial population
Study Population The study will include patients presenting with ST-elevation myocardial infarction (STEMI) who are eligible for and undergoing primary percutaneous coronary intervention (PCI) at Assiut University Heart Hospital.
Trial design
Design model
Cohort
Time perspective
Prospective
Treatments tested in this trial
Not listed
Trial groups
100 Participants
are grouped into 1 trial groupGroup A: Two groups will be measured
Trial outcomes
Primary outcomes
1
Change in inflammatory markers
reactive protein \[CRP\] and tumor necrosis factor-alpha \[TNF-α\]) at 1 month post-primary PCI compared between the intervention group (Bempedoic Acid) and the control group.
Time frame
At 1 month post-PCI.Secondary outcomes
1
Final TIMI flow grade post-PCI.
Assessment of final TIMI flow grade, incidence of no-reflow phenomenon, and occurrence of contrast-induced nephropathy (CIN) after primary PCI.
Time frame
1 day2
Major Adverse Cardiac Events
Incidence of a composite endpoint including heart failure, reinfarction, rehospitalization for cardiac causes, arrhythmia, stroke, and cardiovascular mortality.
Time frame
Within 30 days post-PCI.3
Lipid Profile Changes
Measurement of total cholesterol, LDL-C, HDL-C, and triglycerides to assess lipid-lowering effect of Bempedoic Acid.
Time frame
At 1 month post-PCI.Locations
Sponsors and contacts
Click on the lead sponsor to view all of their trials.
Source ClinicalTrials.gov
This trial is not recruiting at the moment. You can still explore other options: